United
States Securities And Exchange Commission
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: June 18, 2015
(Date of earliest event reported)
ISORAY, INC.
(Exact name of registrant as specified in
its charter)
Minnesota |
001-33407 |
41-1458152 |
(State or other jurisdiction
of incorporation) |
(Commission
File Number) |
(IRS Employer
Identification No.) |
350 Hills Street, Suite 106, Richland,
Washington 99354
(Address of principal
executive offices) (Zip Code)
(509) 375-1202
(Registrant's telephone number)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities
Act |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act |
Item 5.02. Departure of Directors or
Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Appointment of New Director
Effective June 18, 2015, the Board, on
the recommendation of the Nominating Committee, appointed Michael (Mick) McCormick to the Board. Mr. McCormick will stand for re-election
at the Company’s fiscal 2016 annual meeting. Mr. McCormick was appointed to serve on the Audit Committee and the Compensation
Committee, and to chair the Nominations and Corporate Governance Committee.
Mr. McCormick, age 52, brings over 25 years
of senior executive positions in global management, sales, and marketing to the Company. He is currently the CEO of Glukos, one
of the fastest growing food energy products in the U.S. He also serves as a founder and partner of GO Intellectual Capital, an
advisory firm specializing in medical, aviation, and financial services. GO Intellectual Capital recently provided consulting services
to DJO Global, a medical device and services company, to expand its product assortment, add new channels of distribution, and market
new category opportunities. Previous to his service with Glukos and GO, Mr. McCormick served as Executive Vice President of Global
Sales and Marketing for Columbia Sportswear from 2006-2012, where his team successfully launched several new patented technologies,
including Omni-Heat® Reflective and Omni-Freeze® Zero. During Mr. McCormick’s tenure, Columbia built an intellectual
property portfolio with over 200 patents. Mr. McCormick started his career with Nike, working in several senior management roles
and ultimately becoming the Director of National Sales, US, prior to his departure in 1999. He also served as Chief Marketing Officer
of Golf Galaxy from 2003-2006 and Executive Vice President of Global Sales and Marketing of Callaway Golf from 2000-2003.
There are no arrangements or understandings
between Mr. McCormick and any other person pursuant to which Mr. McCormick was selected as a director and there are no transactions
in which Mr. McCormick has an interest requiring disclosure under Item 404(a) of Regulation S-K. Mr. McCormick has been determined
to be “independent” within the meaning of applicable NYSE MKT and SEC rules.
For his service as a director, Mr. McCormick
will be entitled to the compensation the Company generally provides to its directors. Effective June 18, 2015, Mr. McCormick was
granted options to purchase 25,000 shares of the Company’s common stock at the closing price of the common stock as of June
18, 2015 under the Amended and Restated 2006 Director Stock Option Plan as part of his director compensation.
In connection with his appointment, the
Company entered into an indemnification agreement with Mr. McCormick, effective as of June 18, 2015, on substantially the same
terms as the agreements previously entered into between the Company and each of its other directors. The Company has previously
filed a form of indemnification agreement entered into by its officers and directors with the Company as Exhibit 10.35 to the Company’s
Post-Effective Amendment No.2 to its Registration Statement on Form SB-2, as filed on October 13, 2006, which form is incorporated
herein by reference.
On June 22, 2015, the Company issued a
press release announcing Mr. McCormick’s appointment to the Board, the text of which is attached hereto as Exhibit 99.1.
Change in Director Compensation
Also on June 18, 2015, the Board, on the
recommendation of the Compensation Committee, changed its compensation. The independent directors will now receive $3,000 per month
for their service, and the Chair of the Audit Committee will receive an additional $1,000 per month. The per meeting fees as disclosed
in the Company’s Proxy Statement filed with the SEC on January 14, 2015 have not been changed. Any employee directors will
not receive any compensation for their service on the Board.
Change in Executive Officer Determination
Also on June 18, 2015, the Board concluded
that Frederic Swindler, IsoRay Medical, Inc.’s Vice President, is no longer an executive officer of the Company. Mr. Swindler
continues to be employed by the Company’s subsidiary as Vice President, but is transitioning to retirement and other employees
are taking over his prior responsibilities.
Item 9.01. Financial Statements and Exhibits
Exhibit |
|
Description |
99.1 |
|
Press release issued by IsoRay, Inc., dated June 22, 2015. |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned,
hereunto duly authorized.
Dated: June 22, 2015
|
IsoRay, Inc., a Minnesota corporation |
|
|
|
|
By: |
/s/ Dwight
Babcock |
|
|
Dwight Babcock, CEO |
Exhibit 99.1
FOR IMMEDIATE RELEASE
IsoRay Announces
Appointment of New Director
Mick McCormick,
Former EVP of Global Sales and Marketing for Columbia Sportswear, Appointed to Board
Richland, WA (June 22, 2015) — IsoRay
Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications,
today announced the appointment, on June 18, 2015, of Michael (Mick) McCormick, former Executive Vice President of Global Sales
and Marketing of Columbia Sportswear, to its Board of Directors.
Mr. McCormick will serve on the Audit
and Compensation Committees of the Board, and will chair the Nominating and Corporate Governance Committee of the Board.
Mr. McCormick brings over 25 years
of senior executive positions in global management, sales, and marketing to the Company. He is currently the CEO of Glukos, one
of the fastest growing food energy products in the U.S. He also serves as a founder and partner of GO Intellectual Capital, an
advisory firm specializing in medical, aviation, and financial services. GO Intellectual Capital recently provided consulting services
to DJO Global, a medical device and services company, to expand its product assortment, add new channels of distribution, and market
new category opportunities. Prior to his service with Glukos and GO, Mr. McCormick served as Executive Vice President of Global
Sales and Marketing for Columbia Sportswear from 2006-2012, where his team successfully launched several new patented technologies,
including Omni-Heat® Reflective and Omni-Freeze® Zero. During Mr. McCormick’s tenure, Columbia built an intellectual
property portfolio with over 200 patents. Mr. McCormick started his career with Nike, working in several senior management roles
and ultimately becoming the Director of National Sales, US, prior to his departure in 1999. He also served as Chief Marketing Officer
of Golf Galaxy from 2003-2006 and Executive Vice President of Global Sales and Marketing of Callaway Golf from 2000-2003.
"Mick’s vision, strategy
and leadership led to the introduction of many innovative best-selling products at Columbia Sportswear,” said Dwight Babcock,
IsoRay’s Chairman of the Board and Chief Executive Officer. "We will deeply benefit from his sales and marketing expertise.
It is difficult to find a director with both a strong background in well-known retail brands including Nike and Columbia Sportswear
and a marketing background in the medical technology arena. We are excited that Mick has the experience and background to assist
us in enhancing our communications and marketing strategies to get our products recognized as national and international brands
by the healthcare community.”
IsoRay’s various products, including
Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite® radiation therapy system, give physicians the ability
to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of a tumor removal
or by placing seeds within the prostate. The ability to precisely place a specified dose of radiation means there is less likelihood
for damage to occur to healthy surrounding tissue compared to other alternative treatments. IsoRay’s cancer fighting products
diminish the ability of the tumor to recur, resulting in important benefits for patients in longevity as well as quality of life.
###
About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding
brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many
benefits and uses of GliaSite® and Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray. Follow
us on Twitter @Isoray.
Contact:
Floyd Stumpf
(954) 360-9998
Info@wwfinancial.com
Safe Harbor Statement
Statements in this news release about
IsoRay's future expectations, including: the advantages of our products and their delivery systems, whether we will benefit from
the addition of Mick McCormick to the Board, whether our products will be recognized as national or international brands by the
healthcare community, and all other statements in this release, other than historical facts, are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for
the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to
note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based
on such factors as physician acceptance, training and use of IsoRay’s products, changing levels of demand for IsoRay’s
current and proposed future products, IsoRay’s ability to reduce or maintain expenses while increasing sales, patient results
achieved using our products in both the short and long term, success of future research and development activities, patient results
achieved when Cesium-131 is used for the treatment of cancers and malignant diseases beyond prostate cancer, IsoRay’s ability
to successfully manufacture, market and sell its products, IsoRay’s ability to manufacture its products in sufficient quantities
to meet demand within required delivery time periods while meeting its quality control standards, the success of our sales and
marketing efforts, IsoRay’s ability to enforce its intellectual property rights, changes in reimbursement rates, changes
in laws and regulations applicable to our products, whether additional studies and protocols are released and support the conclusions
of past studies and protocols, whether ongoing patient results with our products are favorable and in line with the conclusions
of clinical studies and initial patient results, whether we, our distributors and our customers will successfully obtain and maintain
all required regulatory approvals and licenses to market, sell and use our products in their various forms, continued compliance
with ISO standards as audited by BSI, and other risks detailed from time to time in IsoRay's reports filed with the SEC.
IsoRay (AMEX:ISR)
Historical Stock Chart
From Mar 2024 to Apr 2024
IsoRay (AMEX:ISR)
Historical Stock Chart
From Apr 2023 to Apr 2024